We analyzed the effect of monensin on 11 cancer-associated pathways and found that monensin inhibits the reporter activities for the Elk1/SRF, AP1, NFκB and STAT pathways, and to a lesser extent the Myc/Max reporter activity. Here, SRF is linked to cancer.